An experimental drug originally developed to treat the flu has shown promising results against the coronavirus and could double the effect of Covid-19, say German scientists.
A drug called zapnometinib, or ATR-002, could potentially stop the spread of the virus in cells and at the same time reduce the immune response that affects the development of severe forms of the disease in the event of coronavirus infection, in vitro experiments have shown. ).
The active ingredient zapnometinib, originally used to develop a drug against influenza, has been shown to be effective in a variety of cell culture models, including against SARS-Cov-2.
This implies wide applicability in the face of the upcoming variants of the coronavirus that we will encounter in the future.
Animal tests are currently underway to confirm the findings.
The results of the study, published last week in the journal Cellular and Molecular Life Sciences, are a good foundation on which the Institute for Drugs and Medical Products approved the Atriva Therapies manufacturer to test the drug in humans.
“This is the first time we have seen any drug double-acting against Covid-19,” said study co-author Stefan Ludwig, a virologist at the University of Munster’s Institute of Virology.
“The positive results of ongoing clinical trials in people could result in immediate approval for the drug as early as this year,” Ludwig said.